Covishield usage highest as precaution dose for Covid, says report

The usage of Covishield has been the highest as the precaution dose for COVID-19 as compared to other vaccines, said Union Health Ministry sources

Coronavirus vaccines, booster shot
Photo: Bloomberg
ANI General News
2 min read Last Updated : Aug 30 2022 | 6:18 PM IST

 

New Delhi [India], August 30 (ANI): The usage of Covishield has been the highest as the precaution dose for COVID-19 as compared to other vaccines, said Union Health Ministry sources on Tuesday.

According to the Ministry of Health and Family Welfare, the cumulative number of Precaution Doses administered in the country so far is 15,66,49,800.

The "COVID Vaccine Amrit Mahotsav" campaign was launched on July 15, 2022, to give an impetus to precaution doses as part of the national COVID vaccination drive. Under the campaign, free precaution doses at all government COVID vaccination Centres for persons aged 18 years and above for 75 days (from July 15 to September 30, 2022) are being provided.

Several meetings with States/UTs and other stakeholders have also been carried out under the leadership of the Union Health Minister Mansukh Mandaviya guiding them on the campaign.

Massive countrywide awareness campaigns have enhanced the mass awareness regarding the Precaution Dose.

Special vaccination camps have been organized on the routes of Char Dham Yatra (Uttarakhand), Amarnath Yatra (Jammu and Kashmir), Kanwar Yatra (all States/UTs of North India) as well as major Melas and congregations.

States/UTs have also been assured of continuous support from the Central government so that processes can be further streamlined and expedited.

The Central Government has also advised states/UTs to avoid the expiry of vaccines through elaborate planning and constant monitoring of processes.

Earlier this month, the Centre approved Biological E's Corbevax as a precaution dose after completion of six months from the date of administration of the second dose of either Covaxin or Covishield vaccines for the population aged above 18 years.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineVaccine

First Published: Aug 30 2022 | 6:18 PM IST

Next Story